Abstract] CRISPR-Cas is a prokaryotic adaptive immune system that prevents uptake of mobile genetic elements such as bacteriophages and plasmids. Plasmid transfer between bacteria is of particular clinical concern due to increasing amounts of antibiotic resistant pathogens found in humans as a result of transfer of resistance plasmids within and between species. Testing the ability of CRISPR-Cas systems to block plasmid transfer in various conditions or with CRISPR-Cas mutants provides key insights into the functionality and mechanisms of CRISPR-Cas as well as how antibiotic resistance spreads within bacterial communities. Here, we describe a method for quantifying the impact of CRISPR-Cas on the efficiency of plasmid transfer by conjugation. While this method is presented in Staphylococcus species, it could be more broadly used for any conjugative prokaryote.
.
c. After ~6 h, check the OD600 of both the recipient and donor strains.
i. Add 900 μl of BHI broth into a spectrophotometer cuvette. Add 100 μl of growing culture of one of the recipient cultures. Mix well.
ii. After blanking with BHI, measure and record the OD600 of this 1:10 dilution of the growing culture.
iii. Repeat steps 2c i and 2c ii with the remaining recipient cultures.
iv. Repeat steps 2c i and 2c ii for the donor culture, substituting TSB for BHI.
v. OD600 of all culture dilutions needs to be greater than 0.20 before proceeding. If the OD600
are not yet high enough, return to the shaker and let grow a while before checking the OD600 again.
d. Calculate the amount of donor and recipient to combine to achieve a 1:4 ratio (recipients:donors) for filter mating, as in the example in Table 1 . j. Cover the plates and leave on the benchtop until the cell suspension has fully dried.
k. Incubate the plates upside-down in a 30 °C incubator overnight.
3. Day 3. Serially diluting and plating recipients and transconjugants a. Warm one BHI agar plate containing neomycin (15 μg/ml) and one BHI agar plate containing both neomycin (15 μg/ml) and mupirocin (5 μg/ml) for each filter from the previous night.
b. In 50-ml centrifuge tubes (one for each filter), add 3 ml of BHI broth without antibiotics.
c. Using sterile forceps, pick each filter off the plate and place it into a 50-ml tube prepared in step 3b. ii. Remove 10 μl of the bacterial suspension from step 3d and add it to the first PCR strip tube, pipetting up and down repeatedly to resuspend (this is the 10 -1 dilution). f. Spot 10 μl of each dilution onto a pre-warmed BHI plate containing neomycin and another containing neomycin and mupirocin (see Note 5) . All dilutions to be plated for recipient colony counting should be plated on the same plate, as in Figure 2A , and all dilutions to be plated for transconjugant colony counting should be plated on an additional plate, as in Figure 2B . i. A 100 to 1,000-fold decrease in conjugation efficiency is typically seen in the presence of a CRISPR system as compared to a strain without a CRISPR system.
Data presentation
Data is typically shown in a bar graph showing the number of both recipients and transconjugants in cfu/ml (colony-forming units per milliliter) on a logarithmic scale, with the calculated conjugation efficiencies accompanying the graph, as in Figure 3 . Other strains can be used as the recipient strain in this assay. S. epidermidis RP62a naturally carries a CRISPR spacer that targets the nickase gene found on conjugative staphylococcal plasmids such as pG0400 (Marraffini and Sontheimer, 2008) . Other CRISPR-containing prokaryotes can be used if they are amenable to receiving conjugative plasmids. An additional important consideration in recipient selection is to make sure that the recipient has a selectable marker that differentiates it from the donor strain. In the case of conjugation assays with S.
epidermidis, S. epidermidis RP62a is resistant to neomycin, so this resistance can be used to select only for transconjugants and not the donor strain itself on Day 3. Recipient strains that do not have differing antibiotic susceptibilities naturally can be transformed with a plasmid harbouring an additional resistance marker (such as pC194 [Ehrlich, 1977] for Staphylococcus).
Whichever plasmid is chosen, ensure its origin is compatible with the conjugative plasmid to allow for maintenance and selection of both plasmids in the transconjugants. If using different selective markers, change antibiotics as appropriate for culturing and plating.
2. Other strains of S. aureus can be used as the donor strain in this assay, as can additional conjugative plasmids. The donor strain needs to be able to perform conjugation with the recipient strain, and RN4220 is very convenient for this conjugation assay as it can perform conjugation with S. epidermidis RP62a and lacks a CRISPR system, allowing for ready uptake and maintenance of plasmids such as pG0400 that could be degraded in a CRISPR-bearing strain. Additional conjugative plasmids can also be used, depending on the CRISPR spacers found within the recipient strain. If testing to see if CRISPR functions in anti-plasmid activity in the recipient strain, a conjugative plasmid that bears a protospacer complementary to a spacer found within the CRISPR array of the recipient must be used. In the case of RP62a, pG0400 naturally has this protospacer, but in many systems, it will likely be necessary to engineer a conjugative plasmid with a protospacer. If using a different conjugative plasmid, change antibiotics as appropriate for culturing and plating. Additionally, if engineering a conjugative plasmid, be sure to follow the rules required for CRISPR targeting in the specific system to be tested, such as following the PAM requirement for Types I and II systems (Mojica et al., 2009) 
